Clinical trial · people
DSIP: longer, less interrupted sleep in 6 people with chronic insomnia
Checked against the paper Clinical trialPublished by PepVault
The takeaway
A small early human study linked one IV dose of DSIP to longer, less broken sleep in chronic insomnia, with the effect starting about an hour after the shot.
- Kind
- Clinical trial
- Studied in
- People
- Number studied
- 6
- Published
- 1981
- Journal
- Experientia
What they tested
The team tested whether synthetic DSIP, given into a vein, changes sleep in people with long-term insomnia.
How the study was done
A small clinical trial in 6 middle-aged adults with chronic insomnia. Each received an acute intravenous dose of synthetic DSIP at 25 nmoles/kg of body weight, and their night sleep was measured.

What they found
After DSIP, people slept longer, slept better, and woke up less often during the night. REM sleep, the dreaming stage, rose slightly. The sleep effect lasted up to 6 h of night sleep but began only in the second hour after the injection. In the first hour there were signs of slightly more wakefulness. No daytime sedation or other side effects were seen.
What it doesn’t show
With only 6 people, this is a very small study, and it tested a single intravenous dose rather than repeated use. It shows nothing about long-term effects or other ways of giving DSIP.
The paper
Schneider-Helmert and Schoenenberger The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia. 1981.
The compound
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.